The concept of a cementless isoelastic monoblock cup made of highly cross-linked polyethylene infused with vitamin E: radiological analyses of migration and wear using EBRA and clinical outcomes at mid-term follow-up.


Journal

BMC musculoskeletal disorders
ISSN: 1471-2474
Titre abrégé: BMC Musculoskelet Disord
Pays: England
ID NLM: 100968565

Informations de publication

Date de publication:
23 Jan 2021
Historique:
received: 02 04 2020
accepted: 17 01 2021
entrez: 24 1 2021
pubmed: 25 1 2021
medline: 15 5 2021
Statut: epublish

Résumé

The newest generation of cementless titanium-coated, isoelastic monoblock cup with vitamin E-blended highly cross-linked polyethylene (HXLPE) was introduced to the market in 2009. The aim of the present study was to obtain mid-term follow-up data including migration and wear analyses. This prospective study investigated 101 primary total hip arthroplasty (THA) cases in 96 patients treated at a single institution. Patients were allowed full weight-bearing on the first day postoperatively. Harris hip score (HHS) and pain and satisfication on a visual analogue scale (VAS) were assessed at a mean follow-up of 79.0 months. Migration and wear were assessed using Einzel-Bild-Roentgen-Analyse (EBRA) software. Radiological acetabular bone alterations and complications were documented. At mid-term follow-up (mean 79.0 months, range: 51.8-101.7), 81 cases with complete clinical and radiological data were analyzed. Utilisable EBRA measurements were obtained for 42 hips. The mean HHS was 91.1 (range 38.0-100.0), VAS satisfaction was 9.6 (range 6.0-10.0), VAS rest pain was 0.2 (range 0.0-4.0), and VAS load pain was 0.6 (range 0.0-9.0). Mean migration was 0.86 mm (range: 0.0-2.56) at 24 months and 1.34 mm (range: 0.09-3.14) at 5 years, and the mean annual migration rate was 0.22 (range: - 0.24-1.34). The mean total wear was 0.4 mm (range: 0.03-1.0), corresponding to a mean annual wear rate of 0.06 mm per year (range: 0.0-0.17). Radiographic analysis did not reveal any cases of osteolysis, and no revision surgeries had to be performed. After using vitamin-E blended HXLPE in cementless isoelastic monoblock cups, there were no obvious signs of osteolysis or aseptic loosening occurred. No patients required revision surgery after mid-term follow-up. Cup migration and wear values were well below the benchmarks considered predictive for potential future failure. The trial registration number on ClinicalTrials.gov : NCT04322916 (retrospectively registered at 26.03.2020).

Sections du résumé

BACKGROUND BACKGROUND
The newest generation of cementless titanium-coated, isoelastic monoblock cup with vitamin E-blended highly cross-linked polyethylene (HXLPE) was introduced to the market in 2009. The aim of the present study was to obtain mid-term follow-up data including migration and wear analyses.
METHODS METHODS
This prospective study investigated 101 primary total hip arthroplasty (THA) cases in 96 patients treated at a single institution. Patients were allowed full weight-bearing on the first day postoperatively. Harris hip score (HHS) and pain and satisfication on a visual analogue scale (VAS) were assessed at a mean follow-up of 79.0 months. Migration and wear were assessed using Einzel-Bild-Roentgen-Analyse (EBRA) software. Radiological acetabular bone alterations and complications were documented.
RESULTS RESULTS
At mid-term follow-up (mean 79.0 months, range: 51.8-101.7), 81 cases with complete clinical and radiological data were analyzed. Utilisable EBRA measurements were obtained for 42 hips. The mean HHS was 91.1 (range 38.0-100.0), VAS satisfaction was 9.6 (range 6.0-10.0), VAS rest pain was 0.2 (range 0.0-4.0), and VAS load pain was 0.6 (range 0.0-9.0). Mean migration was 0.86 mm (range: 0.0-2.56) at 24 months and 1.34 mm (range: 0.09-3.14) at 5 years, and the mean annual migration rate was 0.22 (range: - 0.24-1.34). The mean total wear was 0.4 mm (range: 0.03-1.0), corresponding to a mean annual wear rate of 0.06 mm per year (range: 0.0-0.17). Radiographic analysis did not reveal any cases of osteolysis, and no revision surgeries had to be performed.
CONCLUSIONS CONCLUSIONS
After using vitamin-E blended HXLPE in cementless isoelastic monoblock cups, there were no obvious signs of osteolysis or aseptic loosening occurred. No patients required revision surgery after mid-term follow-up. Cup migration and wear values were well below the benchmarks considered predictive for potential future failure.
TRIAL REGISTRATION BACKGROUND
The trial registration number on ClinicalTrials.gov : NCT04322916 (retrospectively registered at 26.03.2020).

Identifiants

pubmed: 33485345
doi: 10.1186/s12891-021-03981-8
pii: 10.1186/s12891-021-03981-8
pmc: PMC7827971
doi:

Substances chimiques

Vitamin E 1406-18-4
Polyethylene 9002-88-4

Banques de données

ClinicalTrials.gov
['NCT04322916']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

107

Références

J Arthroplasty. 2002 Aug;17(5):649-61
pubmed: 12168184
Lancet. 2007 Oct 27;370(9597):1508-19
pubmed: 17964352
J Bone Joint Surg Am. 2005 Oct;87(10):2323-34
pubmed: 16203901
Clin Orthop Relat Res. 2015 Dec;473(12):3806-10
pubmed: 26373851
J Bone Joint Surg Am. 2018 Jan 17;100(2):107-114
pubmed: 29342060
J Bone Joint Surg Br. 1998 May;80(3):377-81
pubmed: 9619922
Acta Orthop. 2020 Jun;91(3):254-259
pubmed: 32098534
Int Orthop. 2011 Oct;35(10):1445-51
pubmed: 20820777
Int Orthop. 2003;27 Suppl 1:S16-9
pubmed: 14565679
Hip Int. 2017 Jul 25;27(4):368-372
pubmed: 28106229
Hip Int. 2016 Jul 25;26(4):386-91
pubmed: 27312329
J Bone Joint Surg Br. 2009 Jul;91(7):855-8
pubmed: 19567846
J Arthroplasty. 2002 Oct;17(7):910-6
pubmed: 12375252
J Bone Joint Surg Br. 1996 May;78(3):422-6
pubmed: 8636179
Biomaterials. 2004 Nov;25(24):5515-22
pubmed: 15142733
J Bone Joint Surg Am. 2008 Feb;90(2):299-306
pubmed: 18245589
Clin Orthop Relat Res. 2001 Dec;(393):137-46
pubmed: 11764343
Biomaterials. 2010 May;31(13):3643-8
pubmed: 20144479
J Biomed Mater Res B Appl Biomater. 2014 Nov;102(8):1627-38
pubmed: 24652696
Clin Orthop Relat Res. 1976 Nov-Dec;(121):20-32
pubmed: 991504
J Arthroplasty. 2010 Jan;25(1):35-40
pubmed: 19056211
Int Orthop. 2005 Feb;29(1):14-7
pubmed: 15490162
Int Orthop. 2011 Feb;35(2):215-23
pubmed: 21120476
J Arthroplasty. 1995 Oct;10(5):636-42
pubmed: 9273375
Acta Orthop. 2020 Dec;91(6):705-710
pubmed: 32835560
J Biomed Mater Res A. 2009 Aug;90(2):549-63
pubmed: 18563825
Clin Orthop Relat Res. 2011 Aug;469(8):2286-93
pubmed: 21132413
J Bone Joint Surg Br. 2008 Oct;90(10):1284-90
pubmed: 18827236
J Arthroplasty. 2015 Apr;30(4):615-21
pubmed: 25496930
J Bone Joint Surg Br. 1995 Nov;77(6):853-61
pubmed: 7593094
J Bone Joint Surg Am. 1973 Dec;55(8):1629-32
pubmed: 4217797
Orthop Traumatol Surg Res. 2014 Jun;100(4 Suppl):S225-9
pubmed: 24703794
J Arthroplasty. 2013 Sep;28(8):1291-6
pubmed: 23523483
Int Orthop. 2017 Jun;41(6):1113-1118
pubmed: 27815591
J Biomech. 1995 Oct;28(10):1225-36
pubmed: 8550641

Auteurs

Yama Afghanyar (Y)

Department of Orthopaedic Surgery, St. Josefs Hospital Wiesbaden, Beethovenstr. 20, 65189, Wiesbaden, Germany. yafghanyar@joho.de.

Sebastian Joser (S)

Department of Orthopaedic Surgery, St. Josefs Hospital Wiesbaden, Beethovenstr. 20, 65189, Wiesbaden, Germany.

Jonas Tecle (J)

Department of Orthopaedic Surgery, St. Josefs Hospital Wiesbaden, Beethovenstr. 20, 65189, Wiesbaden, Germany.

Philipp Drees (P)

Department of Orthopaedics and Traumatology, University Medical Centre of the Johannes Gutenberg-University of Mainz, Langenbeckstraße 1, 55131, Mainz, Germany.

Jens Dargel (J)

Department of Orthopaedic Surgery, St. Josefs Hospital Wiesbaden, Beethovenstr. 20, 65189, Wiesbaden, Germany.

Philipp Rehbein (P)

Department of Orthopaedic Surgery, St. Josefs Hospital Wiesbaden, Beethovenstr. 20, 65189, Wiesbaden, Germany.

Karl Philipp Kutzner (KP)

Department of Orthopaedic Surgery, St. Josefs Hospital Wiesbaden, Beethovenstr. 20, 65189, Wiesbaden, Germany.
Department of Orthopaedics and Traumatology, University Medical Centre of the Johannes Gutenberg-University of Mainz, Langenbeckstraße 1, 55131, Mainz, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH